NANOPARTICLES & MICROPARTICLES TO COMBAT ANTIMICROBIAL RESISTANCE
Dr Anjana Jayasree,
Postdoctoral Research Fellow
School of Pharmacy and Pharmaceutical Sciences
The University of Queensland, Australia
RESEARCHER PROFILE
Filmed in Brisbane, Australia | December 2025
Dr Anjana Jayasree is an emerging research leader in biomaterials, tissue engineering and nanotechnology, recognised internationally for her innovative work on antimicrobial nanoparticles and regenerative therapies. A Postdoctoral Research Fellow at The University of Queensland, she operates at the intersection of materials science, drug delivery and cellular biology, developing advanced metallic-based nanotechnologies to improve both human and animal health outcomes. Her expertise spans nanoparticle synthesis, cell–material interactions, and the design of sophisticated in vitro models to investigate soft-tissue integration, osseointegration, angiogenesis and biofilm formation.
A central pillar of Dr Jayasree’s research is the engineering of next-generation metallic implants with precisely tailored surface modifications that enhance cellular attachment while simultaneously minimising bacterial colonisation and biofilm formation. By integrating bioactive ions, nanoscale architectures and smart antibacterial coatings, her work aims to accelerate healing, strengthen soft-tissue integration and significantly reduce implant-associated infection rates. This multidisciplinary program positions her at the forefront of innovation in regenerative dentistry and biomaterials-driven solutions to antimicrobial resistance.
Beyond her research, Dr Jayasree is a passionate advocate for STEM education and public engagement. She contributes to national outreach programs including Soapbox Science, the Kids STEM Convention and the Wonder of Science Young Science Ambassador initiative, inspiring the next generation of scientists through hands-on learning and accessible communication.
Driven, collaborative and highly creative, Dr Jayasree continues to advance impactful research that bridges fundamental science with real-world clinical and industry needs.
Source: Supplied
https://orcid.org/0000-0003-4719-0174
-
Personalised approaches to lung therapy
Dr. Adams’ research focus is on lung cancer, which is the deadliest of all cancers worldwide. He is working towards developing personalised approaches to pinpoint a therapy that is going to be most effective for the person with that disease. Dr. Adams’ research is focusing on chemotherapy and targeted therapy, and he is trying to identify upfront which of those tumours are likely to be resistant to the therapy. He then identifies strategies that will resensitize or increase the sensitivity of the tumour to the standard of care that is targeted therapy or chemotherapy.
-
Systems genetics to determine risk of developing diabetes complications
Professor Morahan invented the term “Systems Genetics” for the science field that examines how genetic variants can affect whole networks of genes and whole systems; there are now several laboratories and institutes of systems genetics around the world. He also developed the next-generation genetic resource, The Gene Mine, the most powerful of its type in the world, used globally in rapid mapping and identification of genes. Collaborators nationally and internationally have tested The Gene Mine for traits and diseases in which they specialise.
-
Biostatistics in Clinical Trials
As a biostatistician working in research and clinical settings, Kate Francis plays a vital role in ensuring all projects adhere to best practice guidelines and are transparently reported. She has served as the lead statistician for the analysis of clinical trials across a broad range of subject areas, including neonatal resuscitation, BCG for allergy and infection, convulsive status epilepticus and her work has been published in the top journals such as The New England Journal of Medicine, JAMA, and The Lancet. Most recently she was awarded the 2025 Excellence in Trial Statistics Award for her work on the PLUSS trial.
